Advanced HER2+Breast Cancer
1 clinical trials · Condition
◉ Watch Advanced HER2+Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (NCT04208178) | Novartis Pharmaceuticals | 2020-07-16 |
Track Advanced HER2+Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.